New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:09 EDTWXWuXi PharmaTech, Pacific Biomarkers announce collaboration
WuXi PharmaTech and Pacific Biomarkers announced a biomarker collaboration. In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
08:02 EDTWXWuXi PharmaTech's STA subsidiary receives approval from Japanese authorities
WuXi PharmaTech announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients and GMP intermediates for branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan, Australia, and New Zealand.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use